Zydus Lifesciences rises as its arm partners with Prolific Machines
Zydus Lifesciences is currently trading at Rs. 1132.45, up by 15.15 points or 1.36% from its previous closing of Rs. 1117.30 on the BSE.
The scrip opened at Rs. 1117.30 and has touched a high and low of Rs. 1,132.45 and Rs. 1100.85 respectively. So far 10940 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1232.00 on 29-Sep-2026 and a 52 week low of Rs. 835.85 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 1,145.70 and Rs. 1,100.85 respectively. The current market cap of the company is Rs. 1,12,877.53 crore.
The promoters holding in the company stood at 75.01%, while Institutions and Non-Institutions held 18.33% and 6.66% respectively.
Zydus Lifesciences’ subsidiary -- Zylidac Bio and Prolific Machines (Prolific) have partnered to scale Prolific’s platform from early development through GMP production. Both companies are headquartered in Emeryville in the San Francisco Bay Area. Prolific’s technology uses light to control protein expression in engineered cell lines, enabling substantial gains in productivity and product quality. The platform combines optogenetics enabled cell lines, illumination systems compatible with standard bioreactors, AI-driven process optimization, and advanced analytics. The technology is particularly useful for difficult-to-express proteins including multi-specific antibodies, fusion proteins, cytokines and other complex modalities.
Under the agreement, Zylidac will first complete a tech transfer of Prolific's process at 50- liter scale to reproduce Prolific's results at the Zylidac site. The companies plan to subsequently scale client programs 250 liters, and into GMP manufacturing scale. Prolific's illumination hardware will work seamlessly with Zylidac's existing bioreactors, eliminating the need for customers to build new manufacturing infrastructure.
The partnership creates an end-to-end development and manufacturing pathway for Prolific’s clients, spanning early development through commercial-scale supply. Programs can start with cell line development at Prolific and move seamlessly a short distance to Zylidac for scale-up, drug substance and drug product manufacturing, fill-finish, and packaging.
